Differential outcomes following 4 weeks of aclidinium/formoterol in patients with COPD: a reanalysis of the ACTIVATE Study
M Koopman, FME Franssen, S Gaffron… - … journal of chronic …, 2022 - Taylor & Francis
Rationale It is difficult to predict the effects of long-acting bronchodilators (LABD) on lung
function, exercise capacity and physical activity in patients with chronic obstructive …
function, exercise capacity and physical activity in patients with chronic obstructive …
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study.
M Koopman, FME Franssen, S Gaffron… - International Journal of …, 2022 - go.gale.com
Rationale: It is difficult to predict the effects of long-acting bronchodilators (LABD) on lung
function, exercise capacity and physical activity in patients with chronic obstructive …
function, exercise capacity and physical activity in patients with chronic obstructive …
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study.
M Koopman, FME Franssen, S Gaffron… - … Journal of Chronic …, 2022 - europepmc.org
Methods In the ACTIVATE study, patients were randomized to aclidinium bromide/formoterol
fumarate (AB/FF) or placebo for four weeks. The primary outcomes included (1) lung function …
fumarate (AB/FF) or placebo for four weeks. The primary outcomes included (1) lung function …
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
M Koopman, FME Franssen… - … journal of chronic …, 2022 - cris.maastrichtuniversity.nl
Rationale: It is difficult to predict the effects of long-acting bronchodilators (LABD) on lung
function, exercise capacity and physical activity in patients with chronic obstructive …
function, exercise capacity and physical activity in patients with chronic obstructive …
Differential outcomes following 4 weeks of aclidinium/formoterol in patients with COPD: a reanalysis of the ACTIVATE study
M Koopman, FME Franssen, S Gaffron… - Int J Chron Obstruct …, 2022 - repositori.upf.edu
Rationale: It is difficult to predict the effects of long-acting bronchodilators (LABD) on lung
function, exercise capacity and physical activity in patients with chronic obstructive …
function, exercise capacity and physical activity in patients with chronic obstructive …
[PDF][PDF] Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
M Koopman, FME Franssen… - … Journal of Chronic …, 2022 - pdfs.semanticscholar.org
Results: A total of 250 patients were randomized to AB/FF (n= 126) or placebo (n= 124).
Patients in the AB/FF group (39.6% women) had moderate-to-severe COPD, static …
Patients in the AB/FF group (39.6% women) had moderate-to-severe COPD, static …
[PDF][PDF] Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
M Koopman, FME Franssen, S Gaffron… - … Journal of Chronic …, 2022 - scienceopen.com
Results: A total of 250 patients were randomized to AB/FF (n= 126) or placebo (n= 124).
Patients in the AB/FF group (39.6% women) had moderate-to-severe COPD, static …
Patients in the AB/FF group (39.6% women) had moderate-to-severe COPD, static …
[HTML][HTML] Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
M Koopman, FME Franssen, S Gaffron… - … Journal of Chronic …, 2022 - ncbi.nlm.nih.gov
Methods In the ACTIVATE study, patients were randomized to aclidinium bromide/formoterol
fumarate (AB/FF) or placebo for four weeks. The primary outcomes included (1) lung function …
fumarate (AB/FF) or placebo for four weeks. The primary outcomes included (1) lung function …
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
M Koopman, FME Franssen, S Gaffron… - … Journal Of Chronic …, 2022 - lirias.kuleuven.be
RATIONALE: It is difficult to predict the effects of long-acting bronchodilators (LABD) on lung
function, exercise capacity and physical activity in patients with chronic obstructive …
function, exercise capacity and physical activity in patients with chronic obstructive …
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
M Koopman, FME Franssen, S Gaffron… - … Journal of Chronic …, 2022 - dovepress.com
Methods: In the ACTIVATE study, patients were randomized to aclidinium
bromide/formoterol fumarate (AB/FF) or placebo for four weeks. The primary outcomes …
bromide/formoterol fumarate (AB/FF) or placebo for four weeks. The primary outcomes …